As Atara Biotherapeutics INC (ATRA) Stock Value Declined, Artal Group Sa Has Lifted by $5.85 Million Its Holding

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) LogoInvestors sentiment is 1.43 in 2019 Q1. Its the same as in 2018Q4. It is without change, as 11 investors sold ATRA shares while 31 reduced holdings. only 15 funds opened positions while 45 raised stakes. 46.79 million shares or 1.13% more from 46.27 million shares in 2018Q4 were reported. Eagle Asset Management Inc invested in 0.33% or 1.54M shares. Canada Pension Plan Inv Board has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Deutsche Bancorp Ag accumulated 128,418 shares or 0% of the stock. Price T Rowe Assoc Inc Md holds 0.01% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1.75 million shares. Citigroup holds 0% or 15,156 shares in its portfolio. Swiss Retail Bank reported 58,300 shares. 6 were reported by Northwestern Mutual Wealth Mngmt. Morgan Stanley reported 1.28M shares. Dimensional Fund LP accumulated 477,551 shares. Bnp Paribas Arbitrage Sa has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Arrowmark Colorado Hldg Ltd Com invested 0.02% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). New York-based Millennium Management Limited Com has invested 0.01% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Northern Tru reported 525,571 shares or 0.01% of all its holdings. 226,977 were accumulated by Ubs Asset Management Americas. Federated Pa has 903,307 shares for 0.09% of their portfolio.

Since June 27, 2019, it had 1 buy, and 0 sales for $39,000 activity.

Artal Group Sa increased its stake in Atara Biotherapeutics Inc (ATRA) by 15% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa bought 150,000 shares as the company’s stock declined 56.31% . The institutional investor held 1.15 million shares of the health care company at the end of 2019Q1, valued at $45.71 million, up from 1.00 million at the end of the previous reported quarter. Artal Group Sa who had been investing in Atara Biotherapeutics Inc for a number of months, seems to be bullish on the $717.67M market cap company. The stock decreased 4.98% or $0.7 during the last trading session, reaching $13.35. About 836,659 shares traded or 1.76% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 60.20% since August 16, 2018 and is downtrending. It has underperformed by 60.20% the S&P500.

Artal Group Sa, which manages about $2.45 billion US Long portfolio, decreased its stake in Argenx Se by 70,000 shares to 200,000 shares, valued at $24.97 million in 2019Q1, according to the filing. It also reduced its holding in Celgene Corp (Call) (NASDAQ:CELG) by 250,000 shares in the quarter, leaving it with 750,000 shares, and cut its stake in Audentes Therapeutics Inc.

More notable recent Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news were published by: Fool.com which released: “Where Will Gilead Sciences Spend Its Cash? – Motley Fool” on May 07, 2019, also Finance.Yahoo.com with their article: “Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc (ATRA) ? – Yahoo Finance” published on June 23, 2019, Benzinga.com published: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” on August 06, 2019. More interesting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were released by: Globenewswire.com and their article: “Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019 – GlobeNewswire” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Notable Two Hundred Day Moving Average Cross – ATRA – Nasdaq” with publication date: February 26, 2019.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Coverage

Among 2 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atara Biotherapeutics has $70 highest and $62 lowest target. $66’s average target is 394.38% above currents $13.35 stock price. Atara Biotherapeutics had 6 analyst reports since February 26, 2019 according to SRatingsIntel. The rating was maintained by Mizuho on Tuesday, February 26 with “Buy”. The company was maintained on Friday, March 22 by Canaccord Genuity.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.